Tocilizumab
Tocilizumab taper increases time to relapse vs. abrupt withdrawal in giant cell arteritis
Tapering tocilizumab leads to a longer relapse-free period in patients with giant cell arteritis, compared with abrupt discontinuation, according to data published in Seminars in Arthritis and Rheumatism.
Kinase Inhibitors
Interleukin-6 Inhibitors
Tocilizumab taper 'reasonable' in giant cell arteritis remission despite flare risk
DESTIN, Fla. — Rheumatologists should consider tapering tocilizumab for patients with giant cell arteritis in remission despite the increased risk for flare, said a speaker at the Congress of Clinical Rheumatology East annual meeting.
FDA approves second tocilizumab biosimilar; first available in IV, subcutaneous forms
The FDA has approved Tyenne, the second tocilizumab biosimilar overall and the first available in both intravenous and subcutaneous formulations, according to a press release from its manufacturer.
VIDEO: ‘Exciting’ approvals for multiple myeloma over the last few years
Celltrion submits application for Actemra biosimilar to FDA
Celltrion USA has submitted a Biologics License Application to the FDA for its tocilizumab biosimilar candidate CT-P47, according to a press release.
US biosimilar market in 2023: Sea change or slow drip?
News pertaining to biosimilars came at a fast and furious pace in 2023.
Abatacept, certolizumab pegol superior to conventional therapy for rheumatoid arthritis
Patients with rheumatoid arthritis who receive abatacept or certolizumab pegol achieve clinical remission at higher rates than those receiving active conventional therapy, according to data published in Annals of the Rheumatic Diseases.
FDA approves first tocilizumab biosimilar for treatment of rheumatoid arthritis, JIA
The FDA has approved Tofidence as the first tocilizumab biosimilar in the United States for the treatment of rheumatoid arthritis and other conditions, according to a statement from the manufacturer.